Latest filing published 10 Nov 2016 for FIVE PRIME THERAPEUTICS INC, €20k.
Insider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +324.4%Entry US$1.64 · Close at T+365 US$6.96
- -49.9%Entry US$3.35 · Close at T+365 US$1.68
- -48.7%Entry US$2.71 · Close at T+365 US$1.39
- +1.8%Entry US$3.35 · Close at T+365 US$3.41
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Peder Jensen: trading record in brief
This profile gathers the share dealings of Peder Jensen across 2 companies, led by Five Prime Therapeutics Inc and Biocryst Pharmaceuticals Inc. Between 12 May 2011 and 9 November 2016, the trades on record add up to 9 filings.
In open-market terms, that means 4 purchases worth €120k on one side and 2 sales worth €953k on the other. The net balance comes to €834k on the selling side. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 3 option exercises. 2016 to date brings no purchases and 2 sales.
In size, the median ticket on the buying side is €24k. Ninety days after publication, 4 purchases show a median change of +4.6%, with the price up in 50% of them. They describe history only and say nothing certain about the share price ahead.
Most recently, on 10 November 2016, the filings show an option exercise worth €20k in Five Prime Therapeutics Inc. The last insider purchase was made public on 17 December 2012, 5,075 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Peder Jensen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,065 shares@ US$5.541.9% of flowCommon StockSEC:0001209191-16-149265:0
- 4,065 shares@ US$7.262.4% of flowCommon StockSEC:0001209191-16-149265:1
- 8,130 shares@ US$55.3037.3% of flowCommon StockSEC:0001209191-16-149265:2
- 12,195 shares@ US$8.498.5% of flowCommon StockSEC:0001209191-16-134219:0
- 12,195 shares@ US$49.5049.8% of flowCommon StockSEC:0001209191-16-134219:1
- 20,000 shares@ US$1.51Common StockSEC:0001127602-12-034080:0Canonical exit: 14 Mar 2013 (T+90)
- 20,000 shares@ US$3.18Common StockSEC:0001127602-12-019433:0Canonical exit: 3 Sept 2012 (T+90)
- 10,000 shares@ US$2.75Common StockSEC:0001127602-11-030111:0Canonical exit: 16 Feb 2012 (T+90)
- 10,000 shares@ US$3.56Common StockSEC:0001127602-11-016473:0Canonical exit: 10 Aug 2011 (T+90)
9 of 9 declarations
